Bioxyne Forges Alliance for Psilocybin Therapies

Bioxyne Limited (AU:BXN) has released an update.

Bioxyne Limited and Swiss-based CY Biopharma have announced a strategic alliance to supply and develop psilocybin-based therapies in Australasia for mental health and pain conditions. Bioxyne’s subsidiary, BLS WHOLESALERS, the only licensed Australian manufacturer of MDMA and psilocybin, will create novel Psilocybin products for clinical trials and patient supply through the Authorized Prescriber Scheme. The collaboration aims to address the significant unmet medical need for patients with treatment-resistant depression and PTSD, offering new hope for effective therapies.

For further insights into AU:BXN stock, check out TipRanks’ Stock Analysis page.